Literature DB >> 7198139

Regional blockade by neuroleptic drugs of in vivo 3H-spiperone binding in the rat brain. Relation to blockade of apomorphine induced hyperactivity and stereotypies.

C Köhler, L Haglund, S O Ogren, T Angeby.   

Abstract

The regional prevention by neuroleptic drugs of specific in vivo 3H-spiperone binding was studied in the rat brain. L-sulpiride, thioridazine and clozapine was found to reduce the 3H-spiperone binding selectively in the olfactory tubercle, septum, substantia nigra region and frontal cortex but not the striatum at dose levels which preferentially block apomorphine (APO) induced hyperactivity. The maximal prevention of specific 3H-spiperone binding by l-sulpiride and clozapine reached 60-80% in the former structures while the displacement of striatal 3H-spiperone binding did not exceed 40%. In contrast to l-sulpiride, thioridazine and clozapine both chlorpromazine and haloperidol reduced the 3H-spiperone binding to the same extent in all regions studied. Chlorpromazine and haloperidol were potent in prevention of striatal 3H-spiperone binding in vivo which reached 60-80% in this structure.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7198139     DOI: 10.1007/bf01249601

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  29 in total

Review 1.  Multiple receptors for dopamine.

Authors:  J W Kebabian; D B Calne
Journal:  Nature       Date:  1979-01-11       Impact factor: 49.962

2.  The nucleus accumbens of rats and dopaminergic mechanisms regulating locomotor behaviour.

Authors:  A R Cools; W M Honig; A J Pijnenburg; J M Van Rossum
Journal:  Neurosci Lett       Date:  1976-12       Impact factor: 3.046

3.  Stereoselective actions of substituted benzamide drugs on cerebral dopamine mechanisms.

Authors:  P Jenner; A Clow; C Reavill; A Theodorou; C D Marsden
Journal:  J Pharm Pharmacol       Date:  1980-01       Impact factor: 3.765

4.  Serotonergic component of neuroleptic receptors.

Authors:  J E Leysen; C J Niemegeers; J P Tollenaere; P M Laduron
Journal:  Nature       Date:  1978-03-09       Impact factor: 49.962

5.  Stereotyped behaviour patterns and hyperactivity induced by amphetamine and apomorphine after discrete 6-hydroxydopamine lesions of extrapyramidal and mesolimbic nuclei.

Authors:  B Castall; C D Marsden; R J Naylor; C J Pycock
Journal:  Brain Res       Date:  1977-03-04       Impact factor: 3.252

6.  Dopamine receptor binding in vivo: the feasibility of autoradiographic studies.

Authors:  M J Kuhar; L C Murrin; A T Malouf; N Klemm
Journal:  Life Sci       Date:  1978-01       Impact factor: 5.037

7.  In vivo [3H]spiperone binding to the rat hippocampal formation: involvement of dopamine receptors.

Authors:  S Bischoff; H Bittiger; J Krauss
Journal:  Eur J Pharmacol       Date:  1980-12-05       Impact factor: 4.432

8.  3H-Spiroperidol labels serotonin receptors in rat cerebral cortex and hippocampus.

Authors:  I Creese; S H Snyder
Journal:  Eur J Pharmacol       Date:  1978-05-15       Impact factor: 4.432

9.  On the significance of regional dopamine metabolism in the rat brain for the classification of centrally acting drugs.

Authors:  B H Westerink; B Lejeune; J Korf; H M Van Praag
Journal:  Eur J Pharmacol       Date:  1977-03-21       Impact factor: 4.432

10.  The nucleus accumbens--possible site of antipsychotic action of neuroleptic drugs?

Authors:  T J Crow; J F Deakin; A Longden
Journal:  Psychol Med       Date:  1977-05       Impact factor: 7.723

View more
  13 in total

1.  Regional distribution and in vivo binding of the atypical antipsychotic drug remoxipride. A biochemical and autoradiographic analysis in the rat brain.

Authors:  C Köhler; A C Radesäter; G Karlsson-Boethius; B Bryske; M Widman
Journal:  J Neural Transm Gen Sect       Date:  1992

2.  Differential attenuation of d-amphetamine-induced disruption of conditional discrimination performance by dopamine and serotonin antagonists.

Authors:  Michael J Dunn; Simon Killcross
Journal:  Psychopharmacology (Berl)       Date:  2006-08-30       Impact factor: 4.530

Review 3.  Mechanisms of action of atypical antipsychotic drugs: a critical analysis.

Authors:  B J Kinon; J A Lieberman
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

4.  Differences in the time course of dopaminergic supersensitivity following chronic administration of haloperidol, molindone, or sulpiride.

Authors:  E S Prosser; R Pruthi; J G Csernansky
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 5.  The newer, 'atypical' antipsychotic drugs--their development and current therapeutic use.

Authors:  T Kendrick
Journal:  Br J Gen Pract       Date:  1999-09       Impact factor: 5.386

6.  Differential effects of continuous administration for 1 year of haloperidol or sulpiride on striatal dopamine function in the rat.

Authors:  N M Rupniak; S Mann; M D Hall; S Fleminger; G Kilpatrick; P Jenner; C D Marsden
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

7.  The paw test: a behavioural paradigm for differentiating between classical and atypical neuroleptic drugs.

Authors:  B A Ellenbroek; B W Peeters; W M Honig; A R Cools
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

8.  Specific in vivo binding of 3H-spiperone to individual lobes of the pituitary gland of the rat. Evidence for the labelling of dopamine receptors.

Authors:  C Köhler; K Fahlberg
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

9.  In vivo labelling of pituitary dopamine D-2 receptors in the male rat using [3H]-raclopride.

Authors:  C Köhler; G Karlsson-Boethius
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

10.  In vivo labelling of rat brain dopamine D-2 receptors. Stereoselective blockade by the D-2 antagonist raclopride and its enantiomer of 3H-spiperone, 3H-N,N-propylnorapomorphine and 3H-raclopride binding in the rat brain.

Authors:  C Köhler; G Karlsson-Boethius
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.